News for Swedish Orphan Biovitrum AB (publ) (SOBIN.MX)

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2024 Earnings Conference Call February 5, 2025 8:30 AM ETCompany ParticipantsGuido Oelkers - Chief...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2024 Q4 earnings call.

Oct 24, 2024 / 12:00PM GMTGuido Oelkers - Swedish Orphan Biovitrum AB(publ)-President - Chief Executive Officer Yeah, thank you so much and welcome everybody. T

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ETCompany ParticipantsGuido Oelkers - CEOHenrik...

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q2 2024 Earnings Conference Call July 16, 2024 8:00 AM ETCompany ParticipantsGuido Oelkers - Chief...

The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2024 Q2 earnings call.

Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

Apr 25, 2024 / 02:00PM GMTOperator Ladies and gentlemen, welcome to the Q1 Results 2024 Conference Call and Live Webcast. I am Alice the Chorus Call operator. (

Swedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q1 2024 Earnings Conference Call April 25, 2024 10:00 AM ETCompany ParticipantsGuido Oelkers - Chief...

/PRNewswire/ -- The Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi" or the "Company") has, based on the authorisation of...

/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) ("Sobi" or the "Company") calls for an Extraordinary General Meeting to be held on 15...

Investor AB is a holding vehicle composed of mostly listed stocks, a large proportion of which are in healthcare sector. Click here to see our take on IVSBF.

/PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the...

Read Investment Analysts’ Upgrades for May 31st (ARLP, ARMK, ASGN, ATCO, BBD, BCKIY, BGRY, BIOVF, BITF, BKNG) at ETF Daily News

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin... | March 17, 2021